Lumida
/NVO
⌘K
Novo Nordisk A/S

Novo Nordisk A/S

NVO
$50.32USD↓-2.25%-1.16 today

MARKET CAP

236.0B

P/E (TTM)

2.2x

FWD P/E

2.2x

DAY RANGE

$50 – $51

52W RANGE

$35
$68

AI Summary

Stalk
StalkMedium

NVO remains in a clear Stage 2 advancing regime with price above rising EMAs and the 50 DMA, but it is currently extended with extreme overbought conditions. Medium-term bias stays bullish, yet short-term timing is neutral. We defer new entries and await a pullback into the rising EMA support zone to be absorbed before committing. Long-term downtrend continues to anchor broader caution.

  • ↑Obesity care sales +22% to DKK 9.2bn; 50% more patients served.
  • ↑Oral Wegovy pill uptake >2× any prior anti-obesity US launch.
  • ↓GLP-1 segment market share declined 9% amid Eli Lilly competition.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Novo Nordisk (NYSE: NVO) is a global healthcare company based in Denmark, recognized as a leader in diabetes care and obesity treatments. The company operates mainly in the biopharmaceutical sector, focusing on innovative solutions for chronic diseases, including diabetes, obesity, and rare blood disorders. With its extensive pipeline of GLP-1 products like Wegovy and Ozempic, Novo Nordisk strives to address significant unmet medical needs, navigating a challenging competitive landscape driven by rising demand for effective obesity management solutions.

Bull says

  • ↑Obesity care sales +22% to DKK 9.2bn; 50% more patients served.
  • ↑Oral Wegovy pill uptake >2× any prior anti-obesity US launch.
  • ↑2026 guidance raised on stronger GLP-1 sales; positive analyst revisions.
  • ↑DKK 38bn committed to dividends and buybacks; dividend yield of 3.6%.
  • ↑Wegovy available in 35 countries, driving international growth opportunities.
  • ↑Strong profitability and earnings yield support R&D investment and expansion.

Bear says

  • ↓GLP-1 segment market share declined 9% amid Eli Lilly competition.
  • ↓Adjusted gross margin dropped to 80.6% as prices were cut.
  • ↓Sales growth now guided to -4% to -12% at CER.
  • ↓Free cash flow fell to DKK 33.6bn from DKK 41.3bn; capex rising to DKK 55bn.
  • ↓High volatility and elevated short interest signal stock risk.
  • ↓Low liquidity and reduced hedge fund interest may limit demand.

Investment themes with NVO

Weight Loss↓ -0.82%

Products and services targeting weight management

LLY · NVO · PFE

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026neutral

Transcript signals

Bull points

  • in 2026, Novo Nordisk is focused on driving competitiveness, progressing our pipeline, and making focused investments towards growth opportunities while delivering returns today.
  • We are excited to continue bringing new Vigovi options to patients. That includes the Vigovi pill in the U.S. and Vigovi HD, also known as high-dose or 7.2 milligram, which is now approved in the U.S., UK, European Union, and Brazil.
  • It is no secret that the Vigovipil is off to a record-breaking start in the US. Since launching it some 16 weeks ago, we have seen over 1 million people using Vigovipil.

Bear points

  • In the first three months of 2026, adjusted sales decreased by 4% driven by lower realized prices, partly offset by GLP-1 volume growth and market expansion.
  • U.S. operations decreased 11%, partially offset by international operations, which grew 6%.
  • Our GLP-1 sales in diabetes decreased by 11%, mainly driven by U.S. operations.
Read full transcript analysis ›